Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Everest Med Reports Results from Trial of Antibiotic for MDR Infections

publication date: Sep 15, 2020

Everest Medicines, a China in-licensing company, reported positive top-line safety results from a China Phase I trial of taniborbactam in multi-drug resistant (MDR) pathogens.  Taniborbactam was tested in combination with cefepime. Everest acquired rights to cefepime-taniborbactam in Greater China and southeast Asia from VenatoRx of Pennsylvania. The two companies are conducting a pivotal Phase III trial of the cefepime-taniborbactam combination in patients with complicated urinary tract infection (cUTI). More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020